Sandoz Inc - Company Profile
Powered by 
All the data and insights you need on Sandoz Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Sandoz Inc Strategy Report
- Understand Sandoz Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sandoz Inc (Sandoz), a subsidiary of Sandoz Group AG, is a generic pharmaceutical company which develops, manufactures and distributes and sells a range of prescription medicines and protein and biosimilars worldwide. The company also provides intermediary products including active pharmaceutical ingredients (APIs), and biotechnology manufacturing services to other companies. It provides active ingredients and finished dosage forms of pharmaceuticals in the areas of dermatology, cancer, cardiovascular, respiratory, metabolism, central nervous system, pain, ophthalmic, gastrointestinal, and hormonal therapies. Sandoz distributes products to wholesalers, pharmacies, hospitals, and other healthcare outlets. Sandoz is headquartered in Princeton, New Jersey, the US.
Headquarters
United States of America
Address
100 College Road West, Princeton, New Jersey, 08540
Website
www.sandoz.com
Telephone
1 609 6278500
Industry
Pharmaceuticals and Healthcare
Revenue (2021)
$9.6B
Sandoz Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Disease Areas: | Aclovate |
| Cardiovascular | Acular Oph Sol 0.5% |
| Anti-Infectives | Adderall |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Acquisitions/Mergers/Takeovers | In March, the company acquired CIMERLI (ranibizumab-eqrn) business from Coherus BioSciences, Inc. |
| 2023 | Spin-off | In October, the company spun off from Novartis. |
| 2023 | Contracts/Agreements | In September, the company entered into a development and commercialization agreement with Samsung Bioepis to provide Sandoz with the rights to commercialize the biosimilar SB17 ustekinumab in Europe and North America. |
Competitor Comparison
| Key Parameters | Sandoz Inc | Viatris Inc | Allergan Finance LLC | Apotex Inc | Bayer HealthCare Pharmaceuticals |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Canada | Germany |
| City | Princeton | Canonsburg | Parsippany | Toronto | Berlin |
| State/Province | New Jersey | Pennsylvania | New Jersey | Ontario | Berlin |
| No. of Employees | - | 38,000 | - | 8,000 | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gilbert Ghostine | Chairman - Designate | Executive Board | 2023 | - |
| Richard Saynor | Chief Executive Officer | Senior Management | - | - |
| Colin Bond | Chief Financial Officer | Senior Management | - | - |
| Steffen Kurzawa | Chief Communications Officer | Senior Management | - | - |
| Carol Lynch | Chief Business Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer